IMPLANET Will Publish Its Financial Results for H1 2019 on September 9th, 2019, After Market Close and Will Hold a Conference Call in French

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:

IMPLANET (Paris:ALIMP) (OTCQX:IMPZY) (Euronext Growth: ALIMP, FR0010458729, eligible for PEA-PME equity savings plans; OTCQX: IMPZY), a medical technology company specializing in vertebral and knee-surgery implants, today informs the market that it will publish its half year financial results on September 9th, 2019 after market close at 5:45pm CEST (Paris time).

On this occasion, Ludovic Lastennet, Chief Executive Officer and David Dieumegard, Chief Financial Officer, will hold a conference call in French on the same day, Monday, September 9th, 2019, at 6:00pm CEST (Paris time), to answer questions from analysts and investors.

To access the conference call in French, please dial +33 (0) 1 70 71 01 59 then the pin code 70492999 # and follow the instructions.

To access the replay in French, which will be available for a 90-day period, please dial: +33 (0) 1 72 72 74 02 /access code: 418865738 # and follow the instructions.

Forthcoming Implanet conferences:

– SRS (Scoliosis Research Society), September 18 -20, Montreal, Canada

– NASS (North American Spine Society), September 25-27, Chicago, USA

Next press release: 2019 First half results, 23 September after market close

About Implanet

Founded in 2007, Implanet is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ® latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Implanet’s tried-and-tested orthopedic platform, which is based on perfect control over the traceability of its products, provides it with a proven ability to promote this innovation. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. Implanet employs 38 staff and recorded 2018 sales of €6.7 million. For further information, please visit www.Implanet.com. Based near Bordeaux in France, Implanet established a US subsidiary in Boston in 2013. Implanet is listed on Euronext™ Growth market in Paris. The Company would like to remind that the table for monitoring the equity line (OCA, OCAPI, BSA) and the number of shares outstanding, is available on its website: http://www.implanet-invest.com/suivi-des-actions-80

Disclaimer

This press release contains forward-looking statements concerning IMPLANET and its activities. Such forward looking statements are based on assumptions that IMPLANET considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of IMPLANET registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on April 16, 2018 under number D.18-0337 and available on the Company’s website (www.implanet-invest.com), and to the development of economic situation, financial markets, and the markets in which IMPLANET operates. The forward-looking statements contained in this release are also subject to risks unknown to IMPLANET or that IMPLANET does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by IMPLANET that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for IMPLANET shares in any country.

Contacts

Implanet

Ludovic Lastennet, CEO

David Dieumegard, CFO

Tel.: +33(0)5 57 99 55 55

investors@Implanet.com

NewCap

Investor Relations

Sandrine Boussard-Gallien

Tel.: +33 (0)1 44 71 94 94

Implanet@newcap.eu

NewCap

Media Relations

Nicolas Merigeau

Tel.: +33 (0)1 44 71 94 94

Implanet@newcap.eu

Staff

Recent Posts

New leadership for the Canadian Institute of Actuaries in its 60th year

Ottawa, Ontario--(Newsfile Corp. - May 29, 2025) - Angelita Graham is taking on the role…

2 hours ago

Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

MADISON, Wis., May 29, 2025 /PRNewswire/ -- Nordic® today announced it has joined the ServiceNow Partner…

2 hours ago

HerMD Launches Virtual Care Platform, Expanding Access to Specialized Women’s Healthcare

Scheduling Now Open; Appointments Begin June 2, 2025 CINCINNATI, May 29, 2025 /PRNewswire/ -- HerMD,…

2 hours ago

MarketsandMarkets’ 360Quadrants Recognizes Top Startups and SMEs in the Gold Nanoparticles Quadrant Report 2025

DELRAY BEACH, Fla., May 29, 2025 /PRNewswire/ -- 360Quadrants has released its latest Gold Nanoparticles Startups/SMEs…

2 hours ago

Highmark Health revenue grows 11% year over year to $8 billion; reports $13 million net income in first quarter of 2025

Allegheny Health Network reports 10% revenue growth, $8 million operating income, more-than-doubles EBITDA year-over-yearHighmark Health…

2 hours ago

Electronic Lab Notebook Market worth US$1.03 billion by 2030 with 7.3% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., May 29, 2025 /PRNewswire/ -- The global Electronic Lab Notebook Market, valued at…

2 hours ago